Karyopharm Therapeutics Inc. - KPTI STOCK NEWS

MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) has chosen its Transparency Solution to meet state and federal reporting regulations. Launched in October 2020, this SaaS-based platform collects, validates, and reports transfers of value to ensure compliance with transparency laws. Karyopharm sought advanced technology and advisory services from MediSpend to manage evolving regulations effectively. Karyopharm is known for its innovative cancer therapies, including the FDA-approved drug XPOVIO®.

Karyopharm Therapeutics (KPTI) announced an oral presentation at the ISIRV-AVG Virtual Conference discussing the Phase 2 clinical study of low-dose selinexor for severe COVID-19 patients. Despite the discontinuation of the trial due to not meeting primary endpoints for the overall population, encouraging results were seen in patients with low LDH/DD, showing a higher discharge rate by Day 14 (78.9% vs. 57.1%; p=0.029). The drug also demonstrated potential anti-inflammatory effects.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has granted stock options for 122,300 shares to 17 new employees, effective September 30, 2020. Each option has an exercise price of $14.60, equal to the stock's closing price on that date. The options will vest over four years, with 25% vesting on the one-year anniversary of employment. Additionally, options will be fully exercisable under certain conditions related to employment termination. Karyopharm is known for its novel cancer therapies and its lead compound, XPOVIO®, has received FDA approvals for multiple indications.

Karyopharm Therapeutics (Nasdaq: KPTI) announced that four abstracts showcasing clinical data on XPOVIO (selinexor) will be presented at the ESMO Virtual Congress from September 19-21, 2020. Key findings include promising combination results of XPOVIO with pembrolizumab in metastatic melanoma, and with carboplatin and paclitaxel in advanced solid tumors. The data indicates significant clinical activity, suggesting potential for further exploration in solid tumors, enhancing Karyopharm's pipeline prospects.

Karyopharm Therapeutics (Nasdaq: KPTI) announced CEO Michael Kauffman's participation in upcoming investor conferences: Baird's 2020 Global Healthcare Conference on September 9 at 10:15 AM ET and Morgan Stanley's 18th Annual Global Healthcare Conference on September 15 at 5:00 PM ET. The events will feature live webcasts accessible via the company's investor section, with replays available for 90 days. Karyopharm is known for its innovative cancer therapies, particularly its lead drug, XPOVIO, which has received multiple FDA approvals for various cancer treatments.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced stock options for 29,600 shares granted to seven new employees as part of a recruitment incentive, with an exercise price of $15.21 per share. The options vest over four years, with 25% vesting on the one-year anniversary of employment. Notably, these options will be immediately exercisable if employment is terminated for 'good reason' or without 'cause' within a year following a change in control. Karyopharm focuses on innovative cancer therapies, including its lead compound, XPOVIO, which has received FDA approval for multiple myeloma and lymphoma.

Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Christy J. Oliger to its Board of Directors. Oliger, previously the Senior VP of Genentech's Oncology Business Unit, brings over 25 years of experience in the biopharmaceutical sector. Her expertise is expected to aid in the development and commercialization of Karyopharm's lead product, XPOVIO, which is already FDA-approved for multiple indications. CEO Michael G. Kauffman emphasized her strategic value for expanding XPOVIO's reach to new patient populations. Oliger aims to contribute to the company's growth and enhance its impact on cancer treatment.

Karyopharm Therapeutics (KPTI) reported second-quarter 2020 financial results, achieving record sales of $18.6 million for XPOVIO despite ongoing COVID-19 challenges. The FDA granted accelerated approval for XPOVIO to treat relapsed DLBCL, marking it as the only oral agent for this indication. The company announced a significant 16% sales increase from Q1 2020 and reported a 47% improvement in progression-free survival in a key clinical study. However, Karyopharm faced a net loss of $46.4 million, largely influenced by increased R&D expenses.

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced on August 3, 2020, the grant of stock options to purchase 27,300 shares of its common stock to three newly-hired employees, effective July 31, 2020. The options have an exercise price of $16.05 per share, equivalent to the closing price on the grant date. These stock options will vest over four years, with 25% vesting on the first anniversary of employment. In case of a change in control event, employees can fully exercise options if terminated for good reason or without cause.